Is Lisata Therapeutics, Inc. (LSTA) a Buy, Sell, or Hold?
NASDAQ : LSTA
Lisata Therapeutics, Inc.
$3.595 USD
$0.1 (2.71%)
- Volume
- 64.28K
- Average Volume
- 103.21K
- Market Capitalization
- $32.74M
- P/E Ratio
- -1.93
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $5.07
- Year Low
- $1.81
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.23
Company Overview
NASDAQ
David J. Mazzo
Biotechnology
Healthcare
LSTA
21
US
USD
Liquidity Metrics
0.00
4.23
4.23
3.94
0.00
Sales & Valuation
$170K
192.57
2.96
-2.40
-1.52
Profitability
-$1.91
-$16.59M
-9618.24%
-9845.88%
-101.90%
-116.30%
P/E Metrics
-1.93
-0.09
-0.09
Analyst Price Target & Rating
2/5
2 Analysts
%
Poll Results
About Lisata Therapeutics, Inc. (NASDAQ:LSTA) Stock
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in Ju ... ne 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
2026-06-26 11:08:00
SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating Lisata Therapeutics, Inc. (NASDAQ: LSTA) on behalf of investors who suffered losses and whether those losses may be recoverable under federal securities laws.
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lisata Therapeutics, Inc. (LSTA)
2026-06-15 16:53:00
Bala Cynwyd, Pennsylvania--(Newsfile Corp. - June 15, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Lisata Therapeutics, Inc. ("Lisata Therapeutics" or the "Company") (NASDAQ - LSTA) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Kuva Labs, Inc. ("Kuva") for $4.00 per share in cash plus two non-tradeable contingent value rights (CVRs), payable as follows: (1) $1.00 per share, in cash, within 12 months of the date on which rights to certepetide in the Greater China region revert to Lisata from Qilu Pharmaceutical; and (2) $1.00 per share, in cash, upon the filing of an NDA or similar registration document by Kuva for approval to commercialize certepetide in any indication in any jurisdiction. The investigation concerns whether the Lisata Therapeutics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders.
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share
2026-06-10 09:38:03
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has agreed to be acquired by privately held Kuva Labs Inc. for $4 per share in cash, plus a contingent value right worth up to an additional $3.00 per share tied to drug development milestones.
Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
2026-06-10 08:00:00
Lisata stockholders to receive $4.00 per share in cash at closing, plus one non-tradeable contingent value right, which represents the contractual right to receive two contingent cash payments of up to an aggregate of $3.00 per share, subject to achievement of specified milestones
Lisata Therapeutics agrees to Kuva Labs buyout at $4 per share
2026-06-10 05:36:00
Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has agreed to be acquired by privately held Kuva Labs Inc. for $4 per share in cash, plus a contingent value...
2026-05-04 14:48:00
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
URGENT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—LSTA, IBCP, HCBN, and SILA
2026-05-04 13:45:05
NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde and Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report.
Frequently Asked Questions
-
What is the current Lisata Therapeutics, Inc. (LSTA) stock price?
-
Lisata Therapeutics, Inc.(NASDAQ:LSTA) stock price is $3.595 in the last trading session. During the trading session, LSTA stock reached the peak price of $5.07 while $1.81 was the lowest point it dropped to. The percentage change in LSTA stock occurred in the recent session was 2.71% while the dollar amount for the price change in LSTA stock was $0.1.
-
LSTA's industry and sector of operation?
-
The NASDAQ listed LSTA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of LSTA?
-
James Nisco | Senior Vice President of Finance, Treasurer, CAO & Principal Financial and Accounting Officer
Kristen K. Buck | Executive Vice President of R&D and Chief Medical Officer
Gregory S. Berkin | Chief Information & Data Protection Officer
John D. Menditto | Vice President of Investor Relations & Corporate Communications
Tariq Imam | Senior Vice President of Business Development & Operations and General Counsel -
How many employees does LSTA have?
-
Number of LSTA employees currently stands at 21. LSTA operates from 110 Allen Road, Basking Ridge, NJ 07920, US.
-
Link for LSTA official website?
-
Official Website of LSTA is: https://www.lisata.com
-
How do I contact LSTA?
-
LSTA could be contacted at phone #908 842 0100 and can also be accessed through its website. LSTA operates from 110 Allen Road, Basking Ridge, NJ 07920, US.
-
How many shares of LSTA are traded daily?
-
The average number of LSTA shares traded daily for last 3 months was 103.21K.
-
What is the market cap of LSTA currently?
-
The market value of LSTA currently stands at $32.74M with its latest stock price at $3.595